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TYROSINE 370 PHOSPHORYLATION OF ATM POSITIVELY REGULATES
DNA DAMAGE RESPONSE

Hong-Jen Lee, M.S.
Advisory Professor: Mien-Chie Hung, Ph.D.

Abstract
Ataxia telangiectasia-mutated (ATM) mediates DNA damage response by
controlling irradiation (IR)-induced foci formation, cell cycle checkpoint, and
apoptosis. However, how upstream signaling regulates ATM is not
completely understood. Here, we show that upon IR stimulation, ATM
associates with and is phosphorylated by epidermal growth factor receptor
(EGFR) at Y370 at the site of double-strand breaks. Depletion of
endogenous EGFR impairs ATM-mediated foci formation, homologous
recombination, and DNA repair. Moreover, ATM Y370F mutant or
pretreatment with an EGFR kinase inhibitor gefitinib blocks EGFR and ATM
association, hinders CHK2 activation and subsequent foci formation, and
increases radio-sensitivity. Thus, we reveal a critical mechanism by which
EGFR directly regulates ATM activation in DNA damage response and ATM
Y370 phosphorylation may serve as a biomarker for radiation and anti-EGFR
combinational therapies.
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CHAPTER 1 INTRODUCTION
1.1 DNA damage response
DNA damage response (DDR) consists of massive signaling network
and maintains genomic stability when mammalian cells are subjected to
exogenous damage agents such as: radiation, radiomimetic chemicals,
cancer therapeutic agents, or endogenous stimuli like reactive oxygen
species and replication errors (Jackson and Bartek, 2009). Among
various DNA lesions, DNA double strand breaks (DSBs) formation is one
of the most injurious lesions to DNA structure and chromatin integrity
(Bensimon et al., 2011). Proteins involve in DDR can be classified into
three categories: sensors, transducers and effectors (Zhou and Elledge,
2000). Sensor proteins in DDR, such as: Ku70-Ku80 heterodimer, Mre11Rad50-NBS1 (MRN) complex or γ-H2AX, are those proteins recognize
broken DNA fragments in a sequence-independent manner and being
recruited to DNA breaks at early time points after DNA damaged
(McGowan and Russell, 2004). Then those sensor proteins recruits more
signal

transducers,

including

three

major

serine/threonine

phosphoinositide-3 kinase like kinases (PIKK): ataxia telangiectasia
mutated (ATM), ATM Rad3-related protein (ATR) and the catalytic subunit
of DNA-dependent protein kinase (DNA-PKcs), to the DSBs through
protein-protein interactions (Lempiainen and Halazonetis, 2009). Such
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protein recruitments and accumulations at DSBs form foci and further
facilitate signal transduction by post translational modification (PTM).
Next, transducer proteins initiate series of signaling cascades to
downstream effectors for execution of cell cycle arrest, DNA repair, foci
formation, transcription or apoptosis.
Although ATM, ATR and DNA-PKcs all serve as important
transducers in DDR, they are activated by various DNA damage stimuli
and involved in different signaling pathway (Ditch and Paull, 2012). ATR
is activated by single stranded DNA lesions formation or collapsed
replication forks, through binding with ATR-interacting protein (ATRIP),
and recruited to the region coated by replication protein A (RPA)
(Cimprich and Cortez, 2008; Flynn and Zou, 2011; Lopez-Contreras and
Fernandez-Capetillo, 2010; Shiotani and Zou, 2009). ATM and DNA-PKcs
are both activated by DSBs induction but associating with diverse protein
complex and initiating different DNA repair signaling pathways. ATM is
recruited to DSBs by association with MRN complex and activated via
autophosphorylation at Serine 1981 (S1981) and regulates homologous
recombination (HR) DNA repair (Derheimer and Kastan, 2010; Lavin and
Kozlov, 2007; Lee and Paull, 2007).
In contract, DNA-PKcs engages in non-homologous end-joining
(NHEJ) DNA repair through association with Ku70-Ku80 heterodimers at
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DSBs (Dobbs et al., 2010; Mahaney et al., 2009; Nagasawa et al., 2011).
However, how mammalian cells command the signaling directions
between HR (ATM/MRN complex) or NHEJ (DNA-PKcs/Ku heterodimers)
remains unclear. Accumulating evidence showed that failure of DNA
repair or impeding appropriate DDR may result into cell death,
chromosomal deletion, translocation or mutation and then contribute to
promote tumor initiation.

1.2 Biological functions and significance of ATM
Ataxia telangiectasia (A-T) is a rare, inherited neurodegenerative
disease which results into difficulties of movement and coordination,
impairment of immune system and predisposition of cancer (Zhang et al.,
1997). Due to missense or nonsense mutation of ATM gene, most A-T
patients do not possess functional ATM protein kinase which plays a
critical role in maintaining genomic stability. ATM gene encodes a 350
kDa protein kinase which consists of N-terminal HEAT (huntingtin,
elongation factor 1A, protein phosphatase 2A A-subunit, TOR) repeats
(Perry and Kleckner, 2003), FAT domain (FRAP, ATM and TRRAP; aa
1960–2566), PI-3 kinase like kinase domain (KD domain, aa 2712–2962)
and C-terminal FATC (FRAP, ATM and TRRAP C-terminal; aa 2963–
3056) domain (Figure 1).
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With treatments of radiation or agents induce DSBs formation,
inactive

ATM

homodimer

dissociates

as

active

monomer

and

autophosphorylates at Serine 367, Serine 1893, Serine 1981 and Serine
2996 (Bakkenist and Kastan, 2003; Bensimon et al., 2010; Kozlov et al.,
2011; Kozlov et al., 2006) (Figure 2). Previous studies demonstrated that
mutations of those ATM autophosphorylation sites disrupt ATM-mediated
DDR signaling pathways in human cells. However, mouse model of ATM
mutations

and

in

vitro

studies

showed

that

those

ATM

autophosphorylation sites are dispensable for ATM activation by DNA
damage stimuli or oxidation (Daniel et al., 2008; Guo et al., 2010; Lee and
Paull, 2005; Pellegrini et al., 2006), suggesting ATM activation may
require addition regulation mechanisms.
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Figure

1

The

protein

kinase

structure

and

post-translational

modifications of ATM.
Schematic representation of ATM protein kinase structure, positions
of autophosphorylation serine residues (S367, S1893, S1981 and S2996),
CDK5-mediated phosphorylation residue (S794) and TIP60-mediated
acetylation residue (K3016). N-term: N-terminal. C-term: C-terminal.
HEAT repeats: huntingtin, elongation factor 1A, protein phosphatase 2A
A-subunit, TOR. FAT domain: FRAP, ATM and TRRAP; aa 1960–2566.
KD domain: PI-3 kinase like kinase domain, aa 2712–2962. FATC domain
FRAP, ATM and TRRAP C-terminal; aa 2963–3056.
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As a serine/threonine kinase, ATM transduces signals in DDR network
through mediating more than seven hundred putative substrates
phosphorylation (Matsuoka et al., 2007), which is identified in a global
proteomic analysis. When recruited to DSBs and associated with MRN
complex, ATM subsequently phosphorylates checkpoint kinase 2 (CHK2)
at Serine 68 or p53 at Serine 15 to regulate cell cycle checkpoint or
apoptosis (Barlow et al., 1997; Matsuoka et al., 2000) (Figure 2). In
addition to serving as a component of MRN complex which accounts for
ATM DSBs recruitment, Nijmegen breakage syndrome 1 (NBS1) is also
an ATM substrate. It had been shown that ATM-mediated NBS1 serine
278 and serine 343 phosphorylation facilitates structural maintenance of
chromosome 1 (SMC1) phosphorylation and cell cycle arrest in S phase
(Kitagawa et al., 2004; Yazdi et al., 2002).

1.3 Post translational modifications of ATM
Several important post translational modifications (PTM) which affect
ATM

functions and activity had been identified by different research

groups. In post-mitotic neurons, cyclin-dependent kinase 5 (CDK5)
directly phosphorylates ATM at serine 794 (S794) upon DNA damage
stimulation (Tian et al., 2009). Mutation of S794 impairs ATM S1981
autophosphorylation and downstream substrates p53 and H2AX functions.

6

Figure 2 ATM activation and downstream signaling pathways.
Upon ionizing radiation (IR) stimulation, inactive homodimer ATM
dissociates as active monomers and is recruited to DSBs by MRN complex.
Subsequently, activated ATM transduces signal to downstream substrates
like p53 or CHK2 through protein-protein interaction and phosphorylation and
mediates cell cycle arrest for DNA repair. M: Mrell. R: Rad50. N: NBS1. P:
phosphorylation.
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Moreover, blockage of CDK5-ATM signaling pathway protects neuron cell
death induced by DNA damage agents, implying that CDK5 mediating
ATM S794 phosphorylation plays a critical role in ATM activation. By
using a systematic

mutagenesis assay, ATM lysine 3016 (K3016)

acetylation, mediated by Tip60 histone acetyltransferase, was shown to
be required for ATM activation and downstream p53 or CHK2
phosphorylation (Sun et al., 2007). Mutation of ATM K3016 not only
abolishes ATM kinase upregulation but also hinders dissociation of ATM
inactive homodimer to active monomer, suggesting ATM K3016
acetylation may play a key role in ATM activation.

1.4 EGFR signaling pathway and cancer
The epidermal growth factor receptor (EGFR) is a well-documented
oncogene and plasma membrane abundant receptor tyrosine kinase
(RTK) which functions at the upstream of various signaling cascades. It
belongs to ErbB (erythroblastic leukemia viral oncogene homolog) family
including EGFR (ErbB-1), HER2 (ErbB-2), ErbB-3 and ErbB-4 (Yarden
and Sliwkowski, 2001). Ligands, such as epidermal growth factor (EGF),
heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AREG),
transforming growth factor-α (TGF-α), betacellulin (BTC), epigen (EPG) or
epiregulin

(EPR),

stimuli

trigger
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EGFR

homodimerization

or

heterodimerization with other ErbB proteins (Ferguson et al., 2003;
Garrett et al., 2002; Ogiso et al., 2002; Olayioye et al., 2000; Yarden and
Sliwkowski, 2001). Such EGFR conformational changes lead to kinase
activity upregulation and subsequently autophosphorylation at multiple
tyrosine (Y) residues including Y992, Y1045, Y1068, Y1086, Y1148 and
Y1173 of the C-terminal region (Linggi and Carpenter, 2006; Olayioye et
al., 2000; Zhang et al., 2006).
EGFR gene mutation or ligands amplification, resulting into EGFR
signaling upsurge which leads to tumor initiation, progression or
metastasis, was observed in types of cancer like breast cancer, head and
neck cancer, lung cancer, colorectal cancer and glioblastoma (Holbro et
al., 2003; Normanno et al., 2005; Normanno et al., 2006; Uberall et al.,
2008; Zandi et al., 2007). Once activated, EGFR rapidly associates with
Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain
containing proteins such as growth factor receptor-bound protein 2
(GRB2) and recruits a cascade of protein kinase to regulate cell cycle,
cell survival and proliferation (Yaffe, 2002). The recruitments and
interactions between EGFR and adaptor proteins like GRB2 initiate
several signaling networks including: the PI3K-AKT pathway (PI3K,
phosphoinositide 3-kinase), the RAS-RAF-MEK-ERK pathway (Ras, rat
sarcoma viral oncogene homologue; RAF,v-raf murine sarcoma viral
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oncogene

homologue;

MEK,

MAPK/ERK

activator

kinase;

ERK,

extracellular signal-regulated kinase), the STATs (signal transducer and
activator of transcription) pathway and the PLCγ-PKC pathway (PLCγ,
phospholipase C-γ PKC, protein kinase C) which serve critical roles in
regulation of cancer cell adhesion, migration, invasion, proliferation and
transformation (Bogdan and Klambt, 2001; Jorissen et al., 2003; Yarden
and Sliwkowski, 2001; Zandi et al., 2007). Monoclonal antibodies against
EGFR (targeting extracellular domain) and small molecular chemical
compounds targeting EGFR kinase domain had been developed and
used in clinical for cancer patient treatments or combinational therapies
(Tebbutt et al., 2013).

1.5 Biological functions of nuclear EGFR
Other than the role of EGFR in traditional signaling pathways,
increasing evidence demonstrated by different group of researchers
showed that some populations of EGFR localizing in the nucleus involve
in gene transcription, cell proliferation, DNA repair, and chemotherapy or
radiotherapy resistance in the last decade (Wang and Hung, 2009; Wang
et al., 2010). Mechanisms triggering plasma membrane bound EGFR
translocate from cell surface to the nucleus can be classified as two types:
ligand-dependent and ligand-independent. In response to EGF ligand
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stimulation, nuclear EGFR associates to the A-T rich sequence (ATRS)
residing in cyclin D1 promoter, turns on downstream genes expression
and increases cancer cell proliferation (Lin et al., 2001). Although EGFR
does not possess DNA binding domain, one group demonstrated that
nuclear EGFR can target another ATRS in iNOS (inducible nitric oxide
synthase) promoter region through binding with transcriptional factor
STAT3 (Lo et al., 2005). Similar to this study, nuclear EGFR was shown
to transactivate Aurora-A promoter by cooperating with STAT5 and
amplify Aurora-A gene expression, which leads to chromosomal instability
and tumorigenesis (Hung et al., 2008).
B-MYB is another transcriptional target of nuclear EGFR upon EGF
stimulation (Hanada et al., 2006). In breast cancer cell, nuclear EGFR
and E2F1 regulate B-MYB gene expression through targeting B-MYB
promoter in an EGFR kinase activity dependent manner. As a tyrosine
kinase, nuclear EGFR was shown to physically associate with PCNA
(proliferating cell nuclear antigen) and phosphorylate PCNA at tyrosine
211 (Y211) residue (Wang et al., 2006). They also showed that EGFRmediated PCNA Y211 phosphorylation is not only required for chromatinbound PCNA stability but also correlates with nuclear EGFR expression
level, suggesting PCNA Y211 phosphorylation may serve as a marker for
overall survival rate of breast cancer patient.
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When discussing the role of nuclear EGFR, one important issue
needs to be addressed is how membrane-bound EGFR translocates from
plasma cell surface to the nucleus. To this point, accumulated data
showed that early stage of EGFR internalization and the association
between EGFR and Importin β1 are critical for EGFR nuclear entry
through nuclear pore complex (Lo et al., 2006). However, the interaction
between EGFR and exportin CRM1 mediates EGFR nuclear export.
Besides, a putative nuclear localization sequence (NLS), containing three
clusters of basic amino acids, identified in EGFR intracellular carboxyl
terminus participates into EGFR nuclear localization as well (Hsu and
Hung, 2007). In fact, EGFR is not the only RTK can be found in the
nucleus among all the ErbB family proteins. It had been shown that fulllength ErbB2 and ErbB3 can both be detected in the nucleus by using
immunohistochemical (IHC) staining, immunofluorescence staining and
transmission electron microscopy (TEM). (Offterdinger et al., 2002; Wang
et al., 2004; Xie and Hung, 1994).

1.6 The role of nuclear EGFR in DNA damage response
In ligand-independent pathway, EGFR can be directed to the
nucleus in response to radiation, UV, H 2 O 2 or therapeutic chemical
compounds stimuli (Wang and Hung, 2009; Wang et al., 2010). DNA-
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PKcs, one of the upstream signal transducer in DDR and regulating NHEJ
repair pathway when DSBs formation, is the most well-documented
protein involving in nuclear EGFR functions in DDR. In 1998, nuclear
EGFR was first reported to associate with DNA-PKcs and Ku70-Ku80
heterodimers in the nucleus by using immunofluorescence staining and
confocal microscopy (Bandyopadhyay et al., 1998). Pretreatment of c225
(cetuximab), a monoclonal antibody against EGFR extracellular domain
not only reduces EGFR kinase activity but impairs DNA-PKcs nuclear
localization and activity, implying the link between nuclear EGFR and
DNA-PKcs.
Similar phenomenon was observed by different group who studied
the role of nuclear EGFR in DDR. They found that radiation induces
EGFR

nuclear

translocation,

association

with

DNA-PKcs

and

consequently increases DNA-PKcs activity and radiosensitivity of cancer
cells (Dittmann et al., 2005a; Dittmann et al., 2005b). Blockade of EGFR
nuclear translocation by monoclonal antibody cetuximab, EGFR and
HER-2 dual kinase activity inhibitor laptinib or cyclooxygenase-2 (COX-2)
inhibitor celecoxib impairs DNA-PKcs kinase activity and function in DNA
repair and sensitizes cancer cells to radiation treatment (Dittmann et al.,
2005b; Dittmann et al., 2008b; Kim et al., 2009). In non-small-cell lung
cancer cells (NSCLC), mutant EGFR carrying with common oncogenic
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tyrosine kinase domain mutations, L858R or DeltaE746-E750 elevates
NSCLC radiosensitivity due to defect of nuclear translocation upon
radiation treatment, suggesting the significance of nuclear EGFR in
radiation therapy (Das et al., 2007).

1.7 Combinational therapy of EGFR inhibitors and radiation
Since EGFR orchestrates upstream signaling pathways in various
types of cancer and radiation activating EGFR had been linked to
radiotherapy resistance, pre-clinical tests which combine EGFR inhibitors
with radiation therapy had become attractive and been conducted. In
2005, researchers observed that combination of EGFR kinase inhibitor
erlotinib (Tarceva) with radiation can increase cell radiosensitivity and
enhance cell apoptosis. Moreover, systemic administration of erlotinib
profoundly shrinks tumor size when combining with radiation treatment in
xenograft mouse model (Chinnaiyan et al., 2005).
By using monoclonal antibody cetuximab combining with radiation,
similar result reported by another group indicated such a combination
therapy demonstrates a cooperative growth inhibitory effect in certain
NSCLC cell lines and xenograft mouse model (Raben et al., 2005).
Another study, which combined with clinically using EGFR kinase inhibitor
gefitinib and radiation, carried out in NSCLC cell lines showed that
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gefitinib delays DSBs repair efficiency and increases cell radiosensitivity
comparing with radiation treatment alone (Tanaka et al., 2008).
As a matter of fact, EGFR inhibitors sensitizing cancer cell in
response to radiation treatment was also observed in head and neck
squamous-cell carcinoma (HNSCC) cell lines (Harari and Huang, 2001;
Huang et al., 1999; Huang and Harari, 2000; Loeffler-Ragg et al., 2008;
Milas et al., 2000). To apply those pre-clinical discoveries to clinical site, a
multinational, randomized clinical study performed with more than four
hundred advanced squamous-cell carcinoma of the head and neck
patients indicated that cetuximab combines with radiotherapy improved
patient survival rate (Bonner et al., 2006).

1.8 Hypothesis
Several

lines

of

evidence

have

demonstrated

that

autophosphorylation of ATM at S367, S1893, and S1981 are individually
required for ATM activation and ATM-mediated DDR in human. However,
more recent studies have indicated that mutation of either the prominent
S1987 autophosphorylation site (corresponds to S1981 in human) or the
three

conserved

autophosphorylation

sites

S367/S1899/S1987

(correspond to S367/S1893/S1981 in human) of ATM in mice had no
effect on ATM-dependent response (Daniel et al., 2008; Pellegrini et al.,
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2006). These findings suggest that other mechanisms may be involved in
DNA

damage-induced

S367/S1893/S1981

activation

of

autophosphorylation.

spectrometry analysis

and

ATM
We

in

addition

performed

a

identified additional IR-triggered

to
mass
ATM

phosphorylation at S85, Y370, T1885, S1891, and S2592 (Figure 4A).
Since ATM is a serine/threonine kinase, the results suggest that
ATM Y370 phosphorylation would require a tyrosine kinase and this
tyrosine kinase may involve in mediation of DDR through regulating this
ATM Y370 phosphorylation (Figure 3).
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Figure 3 Model depicting project hypothesis
Since

our

preliminary

results

showed

ATM

is

tyrosine

phosphorylated at Y370 in response to IR stimulation, we propose that
tyrosine kinase (Tyr-kinase) mediating this Y370 phosphorylation event
may regulate ATM functions in DDR.
autophosphorylation

S1981.

P

phosphorylation.
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in

P in red circle: ATM

purple

circle:

ATM

Y370

CHAPTER 2 MATERIALS AND METHODS
2.1 Nuclear fractionation, Western blotting and immunoprecipitation
assays
Nuclear fractionation and Western blotting were performed as
described previously (Yu et al., 2012). Briefly, after serum starvation
overnight, cells were treated with or without IR, washed with
phosphate buffer saline (PBS) twice, and resuspended in lysis buffer
(20 mM HEPES pH7.0, 10 mM KCl, 2 mM MgCl 2 , 0.5% Nonidet P-40,
1 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, and 2 µg/ml aprotinin) on ice.
After homogenizing cells with 25-30 strokes in Dounce homogenizer
and centrifugation at 1,500 x g for 5 min, supernatant was separated
as cytosolic extract (CE) and nuclear pellets were wash with lysis
buffer for three times and lysed in TGN buffer (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 1% Tween 20, 0.3% NP-40, 1 mM NaF, 1 mM Na 3 VO 4 ,
1 mM PMSF, and 1X protease inhibitor mixture; Roche) (Yang and
Kastan, 2000) with sonication.
Both nuclear extracts (NE) and CE were collected from
supernatant after centrifugation at highest speed for 10 min at 4°C and
protein concentration was determined by using BCA protein assay kit
(Thermo Scientific). At least 2 mg of NE was applied to subsequent
immunoprecipitation (IP) assay. Anti-EGFR (SC-03, 1:1,000; Santa
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Cruz), anti-ATM (1:1,000; Bethyl Lab), anti-Lamin A (1:2,000; Santa
Cruz), anti-tubulin (1:10,000; Sigma), anti-Flag (1:2,000; Sigma), antiMyc (1:10,000; Roche), anti-phospho-EGFR Y1086 (1:2,000; Cell
Signaling) and anti-phosphotyrosine

(4G10, 1:3,000; Millipore)

antibodies were used in western blotting. Antibodies against phosphoNBS1 S343 (1:2,000; Cell Signaling), NBS1 (1:40,000; Novus), Rad50
(1:10,000; GeneTex), Mrell (1:20,000; GeneTex), phospho-ATM
S1981 (1:4,000; R&D system) and ORC2 (1:2,000; Cell Signaling)
were used in detection of DNA damage response signaling. For
immunoprecipitation, 5 µg of anti-phosphotyrosine antibody (4G10;
Millipore), 2 µg of anti-EGFR antibody (Ab-13, Thermo Scientific) or 5
µg of anti-ATM antibody (Bethyl Lab) was used in 2 mg of nuclear
extracts, respectively.

2.2 Chromatin enriched fractionation
EGFR knockdown (shRNA EGFR #1 and #2) or vector control
HeLa cells were treated with or without 10 Gy IR. After IR, cells were
washed by ice-cold PBS twice, resuspended with buffer A (10 mM
HEPES pH7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10%
glycerol, 1 mM DTT, 0.1% Triton X-100, and 1X protease inhibitor
cocktail mixture (Roche)) and gentle rotated at 4℃ for 30 min. After
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centrifugation at 6,500 x g for 5 min, pellets were washed with 1mL
buffer A (without Triton X-100) once, resuspend with 1 mL of buffer B
(3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, and 1X protease inhibitor
mixture), and gently rotated at 4°C for 30 min. After centrifugation at
6,500 x g for 5 min, pellets were washed with 1 mL of wash bufferⅠ(3
mM EDTA, 0.2 mM EGTA, 10 mM Tris-HCl, pH8.0, and 150 mM NaCl)
and gently rotated at 4°C for 15 min. This step was repeated with
wash buffer Ⅱ (3 mM EDTA, 0.2 mM EGTA, 10 mM Tris-HCl, pH8.0,
and 250 mM NaCl). Cell pellets were lysed with TGN buffer, sonicated,
and applied to centrifugation at 16,000 x g for 10 min at 4°C.
Chromatin-enriched fraction was collected from the supernatant for
subsequent Western blot analysis.

2.3 Immunofluorescence staining for irradiation-induced foci formation
For detection of p-ATM S1981 irradiation-induced foci formation
(IRIF), EGFR-depleted HeLa cells were exposed to 2 Gy or 10 Gy IR
and subjected to staining as previously described13. To detect whether
ATM Y370F impaired p-ATMS1981 or p-CHK2 T68 IRIF, ATMdepleted HeLa cells were transfected with pcDNA3 vector alone, Flagtagged ATM wild type (WT) or Y370F by using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instruction.
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Post transfection for 24 h, cell transfectants were seeded on
cover slides for subsequent IRIF staining as previous procedure. For
detection of p-CHK2 IRIF, U2OS or HeLa cells were washed with PBS
three times, fixed and permeabilized as previously described (Peng et
al., 2009) then subjected to staining. Antibodies against phospho-ATM
S1981 (1:200; Rockland Immunochemicals), phospho-CHK2 T68
(1:200; Cell Signaling), Flag (1:200; Cell Signaling), and phosphoH2AX S139 (1:200; Cell Signaling) were used in detection of IRIF.

2.4 KillerRed system
KillerRed (KR; Figure 7D) is a light-stimulated ROS-inducer fused
to a tet-repressor (tetR-KR), which binds to a TRE cassette (~ 90 kb)
integrated at a defined genomic locus in U2OS cells (U2OS TRE cell
line) (Lan et al., 2010). KR facilitates the formation of oxygen radicals
and superoxide through the excited chromophore (Carpentier et al.,
2009; Pletnev et al., 2009) to induce DNA damage. By targeting the
expression of KR to one specific genome site, we can visualize the
recruitment of proteins at genetic loci. To activate KR, tetR-KR was
exposed to 559 nm laser light for 50 scans (over a total of 10 s) at a
power rate of 1 mW/scan (equal to 50 mW).
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At “the KR-TRE array” induced localized damage, we have
detected γ-H2AX at the site of tetR-KR but not tetR-monomer cherry
(tetR-mcherry) after laser light exposure (Lan et al., 2013) For
bleaching KR, a 559 nm laser (1 mW/scan) in a selected area was
used (FV1000 SIM Scanner set with 405 nm laser diode, Cat.
F10OSIM405, Olympus). The dose that was delivered to the KillerRed
spot was calculated based on the pixel size, the pixel size for
irradiation is (0.138 um/pixel) and the dwell time per pixel is (8
us/pixel). The irradiation is at 1.0 mW (1.0 mJ/s). With a dwell time of
8 us/pixel, this irradiates each pixel with 8.0 nJ/pixel/scan. Multiplying
by the number of scans gives the total energy per pixel.

2.5 Laser microirradiation
The

Olympus

FV1000

confocal

microscopy

system

was

employed (Cat. F10PRDMYR-1, Olympus, UPCI facility) and FV1000
software was used for acquisition of images. For inducing DNA
damage, cells are irradiation 405 nm laser irradiation. The output
power of the laser (original 50mW) passed through the lens was 5
mW/scan. Laser light was passed through a PLAPON 60x oil lens
(super chromatic abe. corr. obj W/1.4NA FV, Cat. FM1-U2B990). Cells
were incubated at 37°C on a thermo-plate (MATS-U52RA26 for
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IX81/71/51/70/50; metal insert, HQ control, Cat. OTH-I0126) in OptiMEM during observation to avoid pH change.

2.6 Neutral comet assay
Neutral comet assay was carried out to determine the levels of
DSB in EGFR-depleted and control HeLa cells according to the
manufacturer’s instruction of Trevigen’s Comet Assay Kit (4250-050-K,
R&D systems). The comet tail movement was measured by using
CometScore software (www.autocomet.com) among more than 100
randomly selected cells in each experiment.

2.7 Cell culture, transient transfection, and viral infection
HeLa cell, U2OS cell, and HEK 293T cell were purchased from
ATCC and maintained in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 medium supplemented with 10% fetal bovine serum. All
cell lines are characterized as mycoplasma negative. For transient
transfection, cells were transfected with indicated plasmids by either
SN liposome (Zou et al., 2002) or Lipofectamine 2000 (Invitrogen). For
lentiviral short hairpin RNA (shRNA) infection, HEK 293T cells were
contransfected with vector control, two various EGFR-targeting or two
different ATM-targeting shRNA with packing plasmids including
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deltaVPR8.2 and envelope plasmid VSVG using SN liposome or
Lipofectamine 2000 according to the manufacturer’s instructions.
Virus-particles containing media was harvested to infect HeLa cell or
U2OS cell after 48 h cotransfection. All the infected cells were
maintained in media containing 0.5 µg/mL puromycin.

2.8 In vitro kinase assay
Equal

amounts

of

purified

GST,

GST-tagged

ATM2

or

ATM2/Y370F protein were incubated with purified recombinant human
EGFR kinase (#7706, Cell Signaling), 10 µCi [γ-32P] ATP, 10 µM ATP
in kinase assay buffer (5 mM MgCl 2 , 5 mM MnCl 2 , 50 µM Na 3 VO 4 , 50
mM HEPES, pH7.4, and 5 mM DTT) at 30°C for 30 min. The kinase
reaction was stopped by addition of SDS samples buffer and boiling.
The samples were analyzed by SDS-PAGE, transferred to PVDF
membrane, and detected by autoradiography. To detect EGFR directly
phosphorylated full-length Flag-tagged ATM, purified Flag-tagged
ATM protein was incubated with or without purified recombinant
human EGFR kinase in the kinase assay buffer as previously
mentioned without [γ-32P] ATP. The resulting signal was detected by
Western blotting with the indicated antibody.
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2.9 Chromatin immunoprecipitation assay
To detect EGFR or ATM localized at DSB sites, DR-GFP
integrated U2OS cells were transiently transfected with vector alone or
I-SceI plasmid as described previously (Peng et al., 2009). After
transfection for 24 h, transfectants were harvested for nuclear
fractionation and intact nuclear pellets were collected for crosslink with
formaldehyde and subsequent ChIP assays by using EZ-ChIP kit
(Upstate) in accordance with the manufacturer’s instructions. AntiEGFR (Thermo Scientific, Ab-13) and anti-pATM S1981 (Rockland
Immunochemicals) antibodies were used for immunoprecipitation.
PCR was carried out with primers flanking the I-SceI restriction
enzyme cutting site shown in Figure 7A.

2.10 Mass spectrometry analysis
Exogenous overexpressed Flag-tagged ATM was isolated from
HeLa cell nuclear extracts by immunoprecipitation using anti-Flag
antibody

and

analyzed

by

SDS-PAGE.

To

identify

novel

phosphorylation sites on ATM, mass spectrometry analysis was
carried out as previously described (Liu et al., 2012).
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2.11 Homologous Recombination (HR) repair analysis
To generate EGFR knockdown stable clones, U2OS cells
containing a single copy of the HR repair reporter substrate DR-GFP
were infected by lentiviral shRNAs targeting to EGFR or vector control,
respectively. After 48-h transfection with mock or I-SceI plasmids
followed by 16-h sodium butyrate (5 mM) treatment, flow cytometry
analysis was carried out to determine the number of HR-repaired
GFP-positive cells.

2.12 Colony formation assay
HeLa cells were re-plated and exposed to various doses of
ionizing radiation (IR) the next day. After 10-day culture, cells were
fixed with Acetic acid:methanol (1:3) solution and colonies were
stained with 0.5% Crystal violet. The number of colonies was
quantitated and results were normalized to plating efficiency.
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CHAPTER 3 ATM IS PHOSPHORYLATED AT TYROSINE 370 (Y370)
UPON IR STIMULATION

3.1 Identification of ATM phosphorylation sites by Mass spectrometry
analysis
Since recent studies have shown that mutation of either the prominent
S1987

autophosphorylation

site

(corresponds

to

S1981,

which

phosphorylation level serves as ATM activation marker in human cells) or the
three conserved autophosphorylation sites S367/S1899/S1987 (correspond
to S367/S1893/S1981 in human) of ATM in mice had no effect on ATMdependent downstream signaling (Daniel et al., 2008; Pellegrini et al., 2006).
These observations suggest that other mechanisms may be involved in DNA
damage-induced activation of ATM in addition to S367/S1893/S1981
autophosphorylation.
To elucidate unknown ATM phosphorylation sties that may regulate
ATM functions in DDR, we performed a mass spectrometry analysis and
identified additional IR-triggered ATM phosphorylation at S85, Y370, T1885,
S1891, and S2592 (Figure 4A). Among these, S85, T1885 and S1891 have
been reported by other groups (Bennetzen et al., 2010; Kozlov et al., 2011;
Matsuoka et al., 2007), which further substantiates the reliability of this mass
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spectrometry analysis. However, detailed functions of ATM S85, T1885 and
T1891 in DDR are not clear.
3.2 ATM Y370 is evolutionary conserved from yeast to mammals
Next, we aimed to figure out whether any ATM phosphorylation residue
we identified in mass spectrometry analysis is evolutionary conserved.
Between the two novel phosphorylation sites Y370 and S2592 identified,
Y370 (Figure 4B) was shown to be evolutionary conserved from yeast to
mammals (but not frog or fruit fly) (Figure 4C), suggesting this Y370
phosphorylation may involve in mediating functions in DDR. Since ATM is a
serine/threonine kinase, the results suggest that ATM Y370 phosphorylation
would require a tyrosine kinase.
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Figure 4 ATM is phosphorylated at tyrosine 370 (Y370) upon IR
stimulation.
A. Mass spectrometry analysis results of immunoprecipitated (IP)
exogenous Flag-tagged ATM from HeLa cell nuclear extracts after 10
Gy IR. Sequence: ATM peptide analyzed by mass spectrometry.
Position: phosphorylation residue on ATM.

B. Mass spectrometry image shows ATM is phosphorylated at Y370
(label as red) after 10Gy IR stimulation.
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Figure 4 ATM is phosphorylated at tyrosine 370 (Y370) upon IR
stimulation.
C. Alignment of ATM partial sequences from human to yeast. Red Y
indicates human ATM tyrosine 370 (Y370) is conserved among all
mammalian species and yeast. Frog possesses shorter form of ATM,
which lacks the N-terminal region.
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CHAPTER 4 EGFR MEDIATES ATM TYROSINE PHOSPHRYLATION

4.1 Identification of kinase mediating ATM tyrosine phosphorylation
To determine which tyrosine kinase might be responsible for ATM
tyrosine phosphorylation after IR stimulation, we first tested a series of
tyrosine kinase inhibitors (TKIs) for their effect on ATM tyrosine
phosphorylation by immunoprecipitation (IP) using 4G10, a pan antiphosphotyrosine antibody. Pretreatment with epidermal growth factor
receptor (EGFR) kinase inhibitors (gefitinib and AG1478) significantly
decreased ATM tyrosine phosphorylation levels (Figure 5A). In contrast,
pretreatments with other TKIs, including imatinib, crizotinib, SU4312,
PD173074, masitinib, and picropodophyllin, did not have any substantial
effects on ATM tyrosine phosphorylation (Figure 5A). These results suggest
that EGFR is a potential tyrosine kinase of ATM.

4.2 ATM is phosphorylated by EGFR in vitro and in vivo
Next, we asked whether EGFR can directly phosphorylate ATM in vitro.
Indeed, results from in vitro kinase assay indicated that EGFR directly
phosphorylated ATM (Figure 5B). In addition, purified human EGFR kinase
domain directly phosphorylated a recombinant GST-ATM2 fragment
(residues 250-522) (Khanna et al., 1998) but not the one containing the
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Y370F

mutation

(Figures

5C).

Moreover,

we

performed

co-

immunoprecipitation (co-IP) assay in 293T cells and found we can only
detect ATM tyrosine phosphorylation when ATM was co-immunoprecipitated
with EGFR wild type (Figure 5D). ATM tyrosine phosphorylation signal was
reduced when co-IP with EGFR kinase dead (KD) mutant or pretreatment of
EGFR kinase inhibitor gefitinib, which strongly suggests that EGFR is a bona
fide kinase of ATM.
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Figure 5 EGFR mediates ATM tyrosine phosphorylation.
A. Identification of kinase mediating ATM tyrosine phosphorylation.
Western blot analysis of HeLa cells nuclear extracts (NE)
pretreated with vehicle (DMSO) or tyrosine kinase inhibitors (TKIs) as
indicated, followed by IR stimulation and IP with pan-pTyr antibody
(4G10). Lamin A and tubulin served as nuclear and cytosolic markers,
respectively. NE indicates nuclear extract. Imatinib, Bcr-Abl kinase
inhibitor; crizotinib, lymphoma kinase, c-ros oncogene 1 receptor
tyrosine kinase (ROS1), and c-Met inhibitor; SU4312, vascular
endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2
and platelet derived growth factor (PDGF) receptor inhibitor;
PD173074, fibroblast growth factor receptor inhibitor; masitinib, stem
cell growth factor receptor (c-kit) and platelet-derived growth factor
(PDGF) receptor inhibitor; picropodophyllin (PPP), insulin-like growth
factor-1 (IGF) receptor inhibitor.
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B. EGFR phosphorylates purified Flag-tagged ATM in vitro.
Purified Flag-tagged ATM proteins were incubated with or without
purified recombinant human EGFR kinase in vitro and analyzed by
Western blotting with indicated antibodies.
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Figure 5 EGFR mediates ATM tyrosine phosphorylation.
C. EGFR phosphorylates purified recombinant GST-ATM2 fragment but
not GST-ATM2/Y370F mutant.
Up panel: schematic of GST only (GST), GST-fused ATM2 and
GST-ATM2-Y370F (GST-ATM2/Y370F) constructs. ATM2 indicates
ATM residues 250-522.
Bottom panel: recombinant GST, GST-ATM2 and GST-ATM2/Y370F
proteins were incubated with purified recombinant human EGFR
kinase (His672-Ala1210) in vitro, analyzed by SDS-PAGE, and
detected by γ-32P exposure (kinase assay) or Coomassie brilliant blue
staining.
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Figure 5 EGFR mediates ATM tyrosine phosphorylation.
D. EGFR kinase activity is required for ATM tyrosine phosphorylation.
HEK 293T cells transfected with the indicated plasmids were
treated by IR stimulation. The resulting cells were harvested for coimmunoprecipitation followed by Western blot analysis. Gefitinib:
EGFR kinase inhibitor.
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CHAPTER 5 EGFR ASSOCIATES WITH ATM IN THE NUCLEUS IN
RESPONSE TO IR

5.1 Endogenous EGFR associates with ATM in the nucleus upon IR
stimulation.
Previously we found EGFR mediates ATM tyrosine phosphorylation
upon IR stimulation, so we hypothesize that EGFR may associate with ATM
in response IR. EGFR has been shown to translocate to the nucleus upon
various stimuli, including IR (Dittmann et al., 2005a; Dittmann et al., 2008a;
Wang and Hung, 2009). We demonstrated that IR not only provoked EGFR
nuclear translocation (Figure 6A) but also induced endogenous EGFR
association with ATM in the nucleus as determined by immunoprecipitation
and reciprocal immunoprecipitation assays using anti-EGFR and anti-ATM
antibodies, respectively, against nuclear extracts (Figures 6B and 6C).
Meanwhile, pretreatment with gefitinib reduced the interaction between
EGFR and ATM (Figures 6B and 6C), suggesting the association between
EGFR and ATM depends on EGFR kinase activity.
EGFR is a plasma membrane abundant protein which locates in the
non-nuclear compartment of cell. We ask whether EGFR binds to ATM in the
cytosolic fraction. As shown in Figure 6D, immunoprecipitation of EGFR
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cannot pull down ATM in the cytosolic fraction, suggesting EGFR only
interacts with ATM in the nucleus.

5.2 EGFR C-terminal CR domain is required for ATM interaction.
To identify which domain of EGFR is responsible for interaction with
ATM, we performed domain mapping of EGFR with ATM by using co-IP
analysis. Among various functional domains (Figure 6E, up panel), the Cterminal regulatory region (CR) domain of EGFR seemed to be required for
its association with ATM (Figure 6E, bottom panel). Together, these results
indicate that EGFR translocates to the nucleus and phosphorylates ATM and
that the CR domain of EGFR is required for ATM interaction upon IR
stimulation.
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Figure 6 Endogenous EGFR associates with ATM in the nucleus upon
IR stimulation.
A. EGFR translocates to the nucleus after IR stimulation.
HeLa cells were serum starved, treated with DMSO or gefitinib,
and stimulated with or without 10 Gy IR. The resulting cells were
harvested

for

nuclear

fractionation,

followed

by

immunoprecipitation assays as shown in Figures 6B, 6C and 6D.
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co-

Figure 6 Endogenous EGFR associates with ATM in the nucleus upon
IR stimulation.
B. EGFR associates with ATM in the nucleus.
Western blot analyses of endogenous EGFR IP products from
NE with indicated antibodies.

C. ATM associates with EGFR in the nucleus.
Western blot analyses of endogenous ATM IP products from NE
with indicated antibodies.
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Figure 6 Endogenous EGFR associates with ATM in the nucleus upon
IR stimulation.

D. EGFR fails to interact with ATM in the cytosolic compartment of cell.
Western blot analyses of endogenous EGFR IP products from
CE with indicated antibodies.

E. EGFR C-terminal CR region is required for ATM interaction.
Up panel: schematic representation of the EGFR domain
structure. Myc-tagged EGFR wild type or truncated mutants including
catalytic region deletion, C-terminal deletion, intra-cellular domain
deletion or extra-cellular domain deletion are designed as WT, ∆CR,
∆C-ter, ECD and ICD, respectively. “+” indicates interaction with ATM.
“-” indicates no interaction with ATM.
Bottom panel: HEK 293T cells were transfected with plasmids as
indicated and harvested for Co-IP assay followed by Western blot
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analysis after IR stimulation. ECD: extracellular domain. TM:
transmembrane. JM: juxtamembrane. KD: kinase domain. CR: Cterminal regulatory region. ICD: intracellular domain. IB: immunoblotting. WCE: whole cell extract.
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CHAPTER 6 EGFR IS RECRUITED TO DSBs IN RESPONSE TO DNA
DAMAGE STIMULI

6.1 EGFR co-localizes with ATM at I-SceI induced DSBs.
ATM is known to be recruited by MRN complex to DSBs in response to
DSBs formation (Derheimer and Kastan, 2010; Uziel et al., 2003) and we
found EGFR associates with and phosphorylated ATM upon IR, implying that
EGFR may be recruited to DSBs like ATM. To investigate whether EGFR is
recruited to DSBs upon DNA damage stimuli, we first carried out chromatin
immunoprecipitation (ChIP) combined with PCR in DR-GFP reporter
integrated U2OS cell system (Figure 7A) (Peng et al., 2009). We found that
exogenous I-SceI expression induced the recruitment of endogenous EGFR
to the DSBs (Figure 7B) similar to activated ATM (p-ATM S1981; Figure 7C).

6.2 EGFR is recruited to DSBs in response to laser light activation.
Then, using a KillerRed light activation system (Figure 7D; detailed
information is described in Materials and Methods) that generates DSBs, we
also showed in Figure 7E that GFP-tagged EGFR signal (indicated by yellow
arrowheads in the lower panels) overlapped with tetR-KillerRed (orange color
in the merged inset), which was not observed in the control (top panels),
further substantiating the localization of EGFR at DSBs upon laser activation.
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Together, these data suggest that EGFR, like ATM, is recruited to DSBs
upon DNA damage stimulation.
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Figure 7 EGFR is recruited to DSBs in response to DNA damage stimuli.
A. Schematic representation of DR-GFP reporter integrated in U2OS cell.
Full-length GFP expression DNA was truncated by I-SceI
restriction enzyme recognition sequence (marked as red). With
exogenous

I-SceI

expression-induced

DNA

DSB,

homologous

recombination efficiency can be determined by full-length GFP
expression by using flow cytometry.
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Figure7. EGFR is recruited to DSBs in response to DNA damage stimuli.
B. EGFR is recruited to I-SceI induced DSBs.
ChIP assay was performed with anti-EGFR antibodies or IgG in ISceI-induced DSBs DR-GFP-integrated U2OS cells. Specific primers
(marked as red arrows in Figure 7A) flanking I-SceI site were used in
PCR to detect activated ATM and EGFR localized at DSBs.
Quantitation of DSB recruitment fold change is presented as mean ±
SD. n = 3. *p < 0.05.
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Figure7 EGFR is recruited to DSBs in response to DNA damage stimuli.
C. Activated ATM is recruited to I-SceI induced DSBs.
ChIP assay was performed with p-ATM S1981 (pATM) or IgG in
I-SceI-induced DSBs DR-GFP-integrated U2OS cells. Specific primers
(marked as red arrows in Figure 7A) flanking I-SceI site were used in
PCR to detect activated ATM and EGFR localized at DSBs.
Quantitation of DSB recruitment fold change is presented as mean ±
SD. n = 3. *p < 0.05.
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Figure7 EGFR is recruited to DSBs in response to DNA damage
stimuli.
D. Schematic representation of the KillerRed system in U2OS TRE cell.
KillerRed is a light-stimulated ROS-inducer fused to a tetrepressor (tetR-KR), which binds to a TRE cassette (~ 90 kb)
integrated at a defined genomic locus in U2OS cells (U2OS TRE cell
line) (Lan et al., 2013; Lan et al., 2010). KR facilitates the formation of
oxygen radicals and superoxide through the excited chromophore
(Carpentier et al., 2009; Pletnev et al., 2009) to induce DNA damage.
By targeting the expression of KR to one specific genome site, we can
visualize the recruitment of proteins at genetic loci.
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Figure7 EGFR is recruited to DSBs in response to DNA damage stimuli.
E. GFP-tagged EGFR is recruited to DSBs in response to laser light.
GFP-tagged

EGFR

and

tetR-mcherry

or

tetR-KR

were

transfected into U2OS TRE cells. The KillerRed spot was activated
with 559 nm laser to induce DNA damage. Representative images
after DNA damage induced by KillerRed activation are shown in the
lower panels. White arrowheads (also shown in enlarged insets): a tetrepressor fused monomer cherry (tetR-mcherry) binds to a TRE
cassette integrated at a defined genomic locus in U2OS cells without
laser light activated DNA damage. Yellow arrowheads (also shown in
enlarged insets): DNA damage sites induced by a tet-repressor fused
KillerRed (tetR-KR) expression and light activation as described in
Figure 7D.
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CHAPTER 7 EGFR CO-LOCALIZES WITH ATM AND γ-H2AX AT DSBs

7.1 EGFR co-localizes with ATM and γ-H2AX at laser irradiationinduced DSBs.
To examine whether EGFR co-localizes with ATM or other DDR
proteins such as γ-H2AX at DSBs, we treated U2OS or HeLa cells by laser
irradiation (Lan et al., 2005; Lan et al., 2004) and found overlapping signals
indicative of co-localization between GFP-tagged (yellow arrowheads, Figure
8A) or endogenous EGFR (yellow arrowheads or enlarged insects, Figure 8B)
and activated ATM (p-ATM S1981) or γ-H2AX (Figure 8C). The results
suggested both endogenous and GFP-tagged EGFR are able to be recruited
to and co-localize with ATM or γ-H2AX at DSBs.

7.2 EGFR associates with MRN complex in the nucleus.
As ATM is recruited to DSBs by Mrell-Rad50-NBS1 (MRN) complex
(Uziel et al., 2003) and activated by MRN in vitro (Lee and Paull, 2004, 2005),
we suspected whether EGFR can also participate into ATM/MRN complex at
DSBs. To this end, we showed that EGFR immunoprecipitation can pull
down the MRN complex in the nuclear extract after IR treatment (Figure 8D).
These results suggest that EGFR may play a role in DDR by associating with
ATM and the MRN complex at DSBs upon IR stimulation.
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Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs.
A. GFP-tagged EGFR co-localizes wit ATM at laser irradiation-induced
DSBs.
GFP-tagged EGFR-transfected U2OS cells were irradiated with
405 nm for 100 ms. After irradiation, cells were fixed and stained with
p-ATM S1981 antibody. Laser microirradiation-induced DSBs is
indicated by yellow arrowheads.
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Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs.
B. Endogenous EGFR co-localizes with ATM at laser irradiation-induced
DSBs.
HeLa cells are irradiated with 405 nm for 60 ms. After irradiation,
cells were fixed and stained with antibodies against EGFR and p-ATM
S1981. Laser irradiation-induced DSBs are indicated by yellow
arrowheads (also shown in enlarged insets).
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Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs.
C. GFP-tagged EGFR co-localizes with γ-H2AX at micro-laser IR induced
DSBs.
GFP-EGFR transfected U2OS cells are irradiated with 405 nm for
100 ms. Fifteen minutes after laser irradiation, cells are fixed and
stained

with

indicated

antibody.

microirradiation-induced DSBs.
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Yellow

arrowheads,

laser

Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs.
D. Nuclear EGFR associates with MRN complex after IR stimulation.
Western blotting analysis of endogenous EGFR IP products from
NE treated with or without IR. NE: nuclear extract. Lamin B: nuclear
fraction marker.
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CHAPTER 8 EGFR IS REQUIRED FOR ATM AND CHK2 IRIF

8.1 EGFR is required for ATM IRIF
As we demonstrated that EGFR phosphorylates and interacts with ATM
upon IR, we suspect that EGFR may participate into DDR like ATM and other
DDR proteins. First, we aimed to determine whether EGFR is required for
ATM downstream functions, such as irradiation-induced foci formation (IRIF)
and DNA repair ability, we generated EGFR knockdown pooled stable clones
using lentiviral-based shRNA targeted against EGFR (up panel, Figure 9A).
Silencing EGFR impaired p-ATM S1981 IRIF (bottom panel, Figure 9A) and
chromatin-enriched

fractionation

also

showed

that

ATM

S1981

phosphorylation levels were lower in EGFR knockdown stable clones from
two different shRNAs than control cells (Figure 9B). Importantly, pretreatment
with EGFR kinase inhibitor gefitinib also abolished p-ATM S1981 IRIF
induced by laser microirradiation (Figure 9C), suggesting EGFR indeed
required for ATM IRIF.

8.2 Depletion of EGFR impairs CHK2 IRIF
CHK2

is

one

of

the

major

ATM

downstream

kinase

which

phosphorylates other DDR proteins and mediates cell cycle checkpoints after
being activated and phosphorylated by ATM at serine 68 (Ward et al., 2001).
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To test whether EGFR involves in ATM downstream signaling, we found
depletion of endogenous EGFR impairs CHK2 IRIF (Figure 9D). Together,
these results indicated that EGFR and its kinase activity are required for ATM
and CHK2 IRIF in DDR.
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Figure 9 EGFR is required for ATM and CHK2 IRIF
A. EGFR is required for ATM IRIF.
Up panel: Western blot analysis of control or two different EGFRknockdown U2OS cells. Bottom panel: Immunofluorescent (IF)
staining of irradiation-induced foci (IRIF) of control or EGFR-depleted
(shEGFR) U2OS cells with indicated antibodies. Quantitation of pATM S1981 and p-CHK2 IRIF is presented as mean ± SD. n =103. *p
< 0.05.
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Figure 9 EGFR is required for ATM and CHK2 IRIF
B. Knocking down endogenous EGFR decreases ATM pS1981 level in
chromatin enrich fractionation.
Chromatin enriched fractionation and WCE of control or EGFRknockdown HeLa cells stimulated with or without IR. Control: shRNA
vector control. #1 and #2 indicate two different clones of shEGFR.
WCE: whole cell extract. ORC2: origin replication complex 2, serving
as a chromatin fraction marker. Tubulin: cytosolic marker.
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Figure 9 EGFR is required for ATM and CHK2 IRIF
C. EGFR kinase activity is required for ATM IRIF.
U2OS cells are treated with or without 10 µM Gefitinib for 16 h
and irradiated with 405 nm for 100 ms. 15 min after irradiation, cells
are fixed and stained with indicated antibody. DAPI: 4,6-diamidio-2phenylindole. Yellow arrowheads, laser microirradiation-induced DSBs.
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Figure 9 EGFR is required for ATM and CHK2 IRIF
D. Depletion of EGFR impairs CHK2 IRIF.
Immunofluorescent (IF) staining of irradiation-induced foci (IRIF)
of control or EGFR-depleted (shEGFR) U2OS cells with indicated
antibodies. DAPI: 4,6-diamidio-2-phenylindole.
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CHAPTER 9 EGFR IS REQUIRED FOR ATM-MEDIATED DAN REPAIR

9.1 Knocking down-EGFR reduces DNA repair ability.
IRIF of p-ATM S1981 is known to activate or recruit DDR proteins such
as NBS1 and BRCA1 to DSBs to execute DNA repair (Cortez et al., 1999;
Kastan and Lim, 2000; Lukas et al., 2011). We next established the link
between EGFR and DNA repair by carrying out a neutral comet assay, which
detects DNA damage level as indicated by comet tail movement. The results
showed that EGFR-silenced cells had four times higher DNA damage levels
than the control-silenced cells, suggesting that EGFR deficiency reduces
DNA repair ability (Figure 10A). To substantiate this finding, we compared
the number of EGFR-knockdown and control cells that contained γ-H2AX foci
as previous reports have indicated that the kinetics of γ-H2AX foci clearance
correlates with mammalian cell radio-sensitivity (MacPhail et al., 2003;
Taneja et al., 2004). Indeed, EGFR-depleted cells demonstrated delayed
DNA repair efficiency as indicated by a higher percentage of cells containing
γ-H2AX foci compared with control cells at 24 and 48 h after IR stimulation
(Figure 10B).

61

9.2 EGFR is required for ATM-mediated homologous recombination
repair.
To further determine whether EGFR is involved in ATM-mediated
homologous recombination repair (Iijima et al., 2008; Morrison et al., 2000),
we generated control and EGFR-depleted U2OS cells integrated with DRGFP reporter (Figure 7A) (Peng et al., 2009). We found that DSBs induced
by exogenous I-SceI expression was efficiently repaired, as indicated by the
number of GFP-expressing cells, in control but not in EGFR-depleted cells
(Figure 10C). All together, these results suggest that EGFR is required for
ATM-mediated IRIF and DNA repair.
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Figure 10 EGFR involves in DNA repair.
A. Depletion of EGFR impairs DNA repair.
Comet assay of EGFR-depleted HeLa cells were carried out with or
without 15 Gy IR. Top: four representative figures showing comet tail
movements (indicated by red bars) in EGFR knockdown or vector
control HeLa cells after IR treatment 6 hours. Bottom: quantitation
from three independent experiments with or without IR exposure. Cells
were measured by CometScore software in each experiment. n=50.
**p < 0.01. Western blot analysis of control or EGFR-knockdown HeLa
cells used in comet assay. Control: EGFR shRNA vector control.
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Figure 10 EGFR involves in DNA repair.
B. Knocking-down endogenous EGFR delays DNA repair.
Quantification of the percentage of cells with an amount of γH2AX foci after IR in control (shCtrl) or two EGFR-depleted
(shEGFR#1 and #2) U2OS cells. Cells were exposed to 5 Gy of
ionizing radiation (IR), fixed after 0, 4 hours, 24 hours and 48 hours
and stained with DAPI and antibodies against γ-H2AX. Percentage of
γ-H2AX foci staining positive cells was quantitated among various
fields. **p < 0.01.
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Figure 10 EGFR involves in DNA repair.
C. EGFR is required for ATM-mediated homologous recombination repair.
Homologous recombination efficiency in DR-GFP reporterintegrated U2OS cells with control or EGFR silencing (shEGFR #1
and #2) was determined by flow cytometry after ectopic expression of
I-SceI. Top: Western blotting showing two EGFR-targeting shRNA #1
and #2 knockdown efficiency in DR-GFP integrated U2OS cells.
Bottom: quantitation of three independent experiments. Ctrl: EGFR
shRNA vector control. *p = 0.02.
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CHAPTER 10 EGFR MEDIATES ATM Y370 PHOSPHORYLATION

10.1 ATM Y370 is a major EGFR-mediated phosphorylation site.
Next, we asked if EGFR phosphorylates ATM at the conserved Y370
and mediates ATM function through this phosphorylation event. Coimmunoprecipitation of Myc-tagged EGFR with Flag-tagged ATM in
HEK293T cells showed that ectopic expression of wild-type (WT) but not
kinase-dead (KD) mutant EGFR enhanced ATM tyrosine phosphorylation in
vivo (Figure 11A). Consistently with the above finding in which gefitinib
pretreatment reduced the association between endogenous EGFR and ATM
(Figures 6B and 6C), we found that only EGFR WT but not KD mutant
interacted with Flag-tagged ATM (Figure 11A). This suggests that the kinase
activity of EGFR is required for its binding with ATM. In addition, the ATM
Y370F mutant decreased its ability to bind to EGFR as well as its levels of
tyrosine phosphorylation, further supporting that Y370 serves a major EGFR
phosphorylation site.

10.2 Generation of AYM pY370 antibody.
To investigate the role of Y370 phosphorylation in vivo, we generated a
specific antibody against ATM Y370 phosphorylation and validated the
specificity of this antibody in which only the phospho-Y370 peptide but not
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the non-phospho-Y370 peptide or other phospho-Y peptides was recognized
(Figure 11B). Using this antibody, we showed that phospho-Y370 level was
decreased when Flag-tagged Y370F but not WT was co-immunoprecipitated
with Myc-tagged EGFR (Figure 11C). Moreover, the levels of phospho-Y370
increased upon IR but reduced when cells were pretreated with gefitinib
(Figure 11D), suggesting that IR-induced ATM Y370 phosphorylation relies
on EGFR’s kinase activity.
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Figure 11 ATM Y370 phosphorylation is mediated by EGFR
A. ATM Y370 serves as a major EGFR phosphorylation site.
HEK 293T cells transfected with the indicated plasmids were
treated by IR stimulation. The resulting cells were harvested for coimmunoprecipitation followed by Western blot analysis.

68

Figure 11 ATM Y370 phosphorylation is mediated by EGFR
B. Characterization of ATM Y370 phosphorylation antibody by using dot
blotting.
Various amounts of peptides were spotted on PVDF membrane
and detected by p-ATM Y370 antibody or amido black staining. IB:
immuno-blotting. ATM pY370: ATM phospho-Y370 peptide. ATM
Y370: ATM non-phospho-Y370 peptide. MCM7 pY600: MCM7
phospho-600 peptide. Lyn pY32: Lyn phosphor-32 peptide (Huang et
al., 2013).
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Figure 11 ATM Y370 phosphorylation is mediated by EGFR
C. Characterization of ATM Y370 phosphorylation antibody by western
blotting.
HEK 293T cells were transfected with plasmids as indicated and
harvested for Co-IP assay followed by Western blot analysis after IR
stimulation.
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Figure 11 ATM Y370 phosphorylation is mediated by EGFR
D. Endogenous ATM is phosphorylated at Y370 upon IR.
Top: Western blot analysis of endogenous ATM IP products from
HeLa cell NE treated with or without IR. Gefitinib: EGFR kinase
activity inhibitor. Bottom: western blot analysis of nuclear fractionation.
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CHAPTER 11 EGFR MEDIATES DDR via ATM Y370
PHOSPHORYLATION

11.1 ATM Y370 phosphorylation facilitates ATM IRIF.
To validate that ATM Y370 phosphorylation responds to IR and
orchestrates DDR, Flag-tagged ATM WT or Y370F mutant was restored in
ATM-depleted HeLa cells to examine its effect on p-ATM S1981 IRIF. As
shown in Figure 12A, re-expression of ATM WT but not of Y370F mutant
rescued p-ATM S1981 IRIF. In addition, compared with ATM WT, recruitment
of ATM Y370F to chromatin induced by IR was significantly reduced as
demonstrated by chromatin-enriched cell fractionation assay (Figure 12B).
These findings suggest that EGFR-mediated ATM Y370 phosphorylation
facilitates p-ATM S1981 IRIF.

11.2 ATM Y370 phosphorylation defective mutant impairs downstream
CHK2 IRIF and NBS1 S343 phosphorylation.
Activated ATM is known to rapidly phosphorylate protein kinase CHK2
at threonine 68 upon IR stimulation to regulate cell cycle arrest (Ahn et al.,
2000; Matsuoka et al., 2000; Ward et al., 2001; Zhou et al., 2000). To
decipher whether ATM Y370 phosphorylation plays a role in mediating
downstream DDR proteins like CHK2, we examined p-CHK2 IRIF in ATM-
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depleted HeLa cells. Re-expression of Flag-tagged ATM WT but not Y370F
mutant rescued p-CHK2 IRIF (Figure 12C), indicating that ATM Y370
phosphorylation is also involved in p-CHK2 IRIF. We further investigated
whether ATM Y370 phosphorylation is also involved S343 phosphorylation of
NBS1, as ATM serves as an upstream kinase in the ATM-NBS1-SMC1
signaling for cell cycle checkpoint (Kitagawa et al., 2004; Lim et al., 2000).
Only Flag-tagged ATM WT but not Y370F in ATM-depleted HeLa cells
reactivated NBS1 S343 phosphorylation (Figure 12D).

11.3 EGFR regulates DNA-PKcs activation through ATM Y370
phosphorylation.
Emerging data demonstrated DNA-PKcs activation depends on
association with nuclear EGFR but detailed mechanism is not clear
(Bandyopadhyay et al., 1998; Dittmann et al., 2005a; Dittmann et al., 2005b).
A recent report indicated that DNA-PKcs activation relies on ATM S1981
phosphorylation (Chen et al., 2007). We found that restoration of Flag-tagged
ATM WT, but not Y370F can rescue DNA-PKcs IRIF, suggesting EGFR
regulates DNA-PKcs via ATM Y370 phosphorylation (Figure 12E). Together,
these results suggest that EGFR-mediated ATM Y370 phosphorylation is
essential for ATM activation, downstream CHK2 and DNA-PKcs IRIF and
NBS1 S343 phosphorylation.
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM
IRIF and downstream signaling
A. ATM Y370 phosphorylation facilitates ATM IRIF.
p-ATM S1981 IRIF staining of ATM-depleted (shATM) HeLa cells
with reconstitution of Flag-tagged ATM wild type (WT) or Y370F
mutant.

Quantitation of p-ATM S1981 IRIF is presented as mean

values ± SD. n =50. **p < 0.01.
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM
IRIF and downstream signaling
B. ATM Y370 phosphorylation defective mutant impairs ATM chromatin
recruitment.
Vector control, Flag-tagged ATM WT, or Y370F was restored in
ATM-depleted HeLa cells (HeLa shATM). After treatment with or
without IR and recovery for 4 hours, chromatin enriched fractionation
was carried out, followed by Western blot analysis with indicated
antibodies.
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM
IRIF and downstream signaling
C. ATM Y370 phosphorylation involves in CHK2 IRIF.
p-CHK2 IRIF staining of ATM-depleted HeLa cells with
reconstituted Flag-tagged ATM WT or Y370F mutant. Quantitation of
p-CHK2 IRIF is presented as mean values ± SD. n =50. **p < 0.01.
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM
IRIF and downstream signaling
D. ATM Y370 phosphorylation defective mutant reduces ATM-mediated
NBS1 S343 phosphorylation.
ATM-depleted HeLa cells were transfected with Flag-tagged ATM WT,
Y370F, or vector alone. Cell transfectants were treated with or without
IR, harvested and analyzed by Western blot with indicated antibody.
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM
IRIF and downstream signaling
E. ATM Y370 phosphorylation recues DNA-PKcs IRIF.
DNA-PKcs IRIF staining of ATM-depleted HeLa cells with
reconstituted Flag-tagged ATM WT or Y370F mutant. Quantitation of
p-DNA-PKcs IRIF is presented as mean values ± SD. n =50. **p <
0.01.
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CHAPTER 12 EGFR MEDIATES RADIO-THERAPY RESISTANCE
THROUGH ATM Y370 PHOSPHORYLATION

12.1 ATM Y370 phosphorylation is essential for ATM-mediated radiotherapy resistance.
Clinically, EGFR inhibitors synergistically sensitize response to radiation
therapy in patients with head and neck squamous cell carcinoma (Bernier et
al., 2009). Since EGFR-mediated ATM Y370 phosphorylation is required for
ATM activation, downstream signaling, and DNA repair, we hypothesized
that ATM Y370 phosphorylation plays a role in radiotherapy resistance.
Indeed, HeLa cell colony formation was reduced in ATM-depleted cells
compared to that in control cells after IR stimulation but was rescued by
reconstitution of only ATM WT but not the Y370F mutant (Figures 13A and
13B), suggesting ATM Y370 phosphorylation is essential for ATM-mediated
DNA repair and radiotherapy resistance.

12.2 ATM-mediated radio-therapy resistance depends on EGFR kinase
activity.
To show that EGFR regulates radiotherapy resistance through EGFR’s
kinase activity, we performed colony formation assay by using various doses
of EGFR kinase inhibitor gefitinib. Consistent with previous findings (Kang et
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al., 2012; Lin et al., 2011; Park et al., 2010), gefitinib combined with IR also
produced a synergistic effect in radio-sensitivity (Figure 13C). Collectively,
our findings uncovered an underlying mechanism by which gefitinib
enhances

radio-sensitivity

through

EGFR-mediated

ATM

phosphorylation to facilitate ATM activation and subsequent DDR.
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Y370

Figure 13 ATM Y370 phosphorylation regulates radio-sensitivity.
A. ATM Y370 phosphorylation is essential for ATM-mediated radiosensitivity.
ATM-depleted HeLa cells were reconstituted with vector control,
Flag-tagged ATM WT, or Y370F and treated with increasing doses of
IR. The cell survival rate was determined by colony formation assay
and presented as mean value ±SD. n = 3. *p < 0.05. **p < 0.01.
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Figure 13 ATM Y370 phosphorylation regulates radio-sensitivity.
B. Western blot analysis of ATM-depleted HeLa cells with restoration of
vector control, Flag-tagged ATM WT or Y370F.
Vector control, Flag-tagged ATM WT, or Y370F was restored in
ATM-depleted HeLa cells (HeLa shATM). After transfection for fortyeight hours, cell lysates were harvested for Western blot analysis with
indicated antibodies.
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Figure 13 ATM Y370 phosphorylation regulates radio-sensitivity.
C. EGFR kinase activity is required for ATM-mediated radiosensitivity.
Colony-forming assay of HeLa cells treated with the indicated
concentration of gefitinib with increasing doses of IR. The cell survival
rate was presented as mean value ±SD. n = 3. **p < 0.01.
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CHAPTER 13 SUMMARY AND DISCUSSION

13.1 Summary
Ataxia telangiectasia-mutated (ATM) functions as one of the upstream
serine/threonine kinases in DNA damage response. Upon formation of DNA
double

strand

breaks

(DSBs),

ATM

is

rapidly

activated

and

autophosphorylated at serine 1981 which then mediates downstream
signaling pathway. However, how ATM is regulated remains unclear. As
shown in the model below (Figure 14), we demonstrate that
1. ATM associates with and is phosphorylated at tyrosine 370 (Y370) by
nuclear epidermal growth factor receptor (EGFR) upon IR stimulation.
2. ATM co-localizes with EGFR at DSBs by using multiple methods
including chromatin immunoprecipitation, KillerRed system, and laser
irradiation.
3. Knocking down EGFR or EGFR kinase inhibitor gefitinib treatment not
only impairs ATM and downstream CHK2 and DNA-PKcs foci
formation but also reduces DNA repair efficiency.
4. EGFR-mediated ATM Y370 phosphorylation facilitates ATM, DNAPKcs and CHK2 foci formation, NBS1 phosphorylation, and enhances
radiotherapy resistance.
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Together, we unravel an EGFR mediated novel mechanism of ATM
activation, downstream signal transduction, and DNA repair efficiency.
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Figure 14 Propose model showing the role of EGFR in ATM-mediated
DNA damage response.
EGFR-mediated ATM Y370 phosphorylation facilitates ATM S1981
autophosphorylation (indicated by “+”) and ATM-mediated DNA damage
response such as DNA-PKcs and CHK2 IRIF. Pretreatment of EGFR kinase
inhibitor (gefitinib) blocks ATM Y370 phosphorylation reduces ATM S1981
autophosphorylation and impairs ATM-mediated DNA damage response.
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13.2 The role of EGFR in cancer cell radio-sensitivity.
The current report reveals a tyrosine phosphorylation of ATM at Y370
by EGFR after IR stimulation. The ATM Y370 phosphorylation event
facilitates not only ATM activation but also ATM-mediated downstream DDR
(Figure

14).

Our

data

indicate

that

EGFR-mediated

ATM

Y370

phosphorylation confers radiotherapy resistance in cancer cells and suggest
ATM phospho-Y370 could serve as a marker to stratify patients for rational
combinational therapy of IR and TKI treatment.
Two different groups have previously reported that erlotinib or gefitinib
pretreatment increases radio-sensitivities of triple-negative breast cancer
(TNBC) and non-small cell lung cancer (NSCLC) cells, respectively (Lee et
al., 2012; Park et al., 2010). The data presented in these studies substantiate
the role of EGFR kinase activity in radiotherapy resistance by demonstrating
that inactivation of EGFR kinase activity enhances radio-sensitivities of
TNBC and NSCLC cells. In fact, Das and colleagues demonstrated EGFR
tyrosine kinase domain mutants in NSCLC cells impaired radiation-induced
EGFR nuclear translocation and significantly delayed DSB repair efficiency
(Das et al., 2007), further providing evidence to support the role of nuclear
EGFR in DDR in our study. Together, our results and other group’s data all
indicate that EGFR kinase activity plays an important role in mediating
various types of cancer cell radio-sensitivity.
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13.3 Tyrosine kinases mediate ATM signaling.
In 2013, Jackson’s group demonstrated that c-Abl regulates ATM
signaling through Y44 phosphorylation of the protein acetyltransferase KAT5
(also known as TIP60), which increases the acetylation level of ATM (Kaidi
and Jackson, 2013). We showed that pretreatment of c-Abl kinase inhibitor
imatinib did not reduce ATM tyrosine phosphorylation as opposed to EGFR
kinase inhibitors gefitinib and AG1478 (Figure 5A), suggesting that c-Abl may
not regulate ATM signaling by direct phosphorylation of ATM. Thus, tyrosine
kinase such as EGFR can directly phosphorylate ATM or like c-Abl can
indirectly regulate ATM through phosphorylation of KAT5.

13.4 The connections among ATM, DNA-PKcs and EGFR.
EGFR has been reported to associate with DNA-PKcs, one of the major
serine/threonine kinases in DDR, to mediate non-homologous end joining
after IR, but the detailed mechanism remains unclear (Bandyopadhyay et al.,
1998; Dittmann et al., 2005a). Chen and colleagues also demonstrated that
activated ATM is essential for DNA-PKcs activation (Chen et al., 2007). They
found that endogenous ATM-depleted cells mediated by shRNA or A-T cells
decreases DNA-PKcs threonine 2609 (T2609) phosphorylation, which is
critical for its role in DSB repair and radiation resistance. Here, we identified
a mechanism in DNA-PKcs IRIF in DDR through EGFR-mediated Y370
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phosphorylation of ATM, filling the gap between ATM signaling and DNAPKcs T2609 phosphorylation. Taken together, our findings indicate that
EGFR plays a critical role in DDR and that phospho-ATM-Y370 has the
potential to serve as a biomarker in radiotherapy or chemotherapy combined
with targeted EGFR inhibitors in cancer treatments.
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CHAPTER 14 FUTURE DIRECTIONS

14.1 Hit and stay model
Our results indicate EGFR associates and co-localizes with ATM at
DSBs upon IR stimulation (Figures 6B, 6C and 8B). Interestingly, we found
that ATM Y370F, a phosphorylation defective mutant of ATM, impairs
association with Myc-tagged EGFR in co-IP experiment (Figure 11A) and
pretreatment of EGFR kinase inhibitor gefitinib also reduces interaction
between endogenous EGR and ATM (Figures 6B and 6C), suggesting both
EGFR kinase activity and ATM Y370 phosphorylation are required for EGFRATM interaction. These findings raise our interest to figure out whether
EGFR mediates ATM and other DDR proteins through a “Hit and Stay model”.
In this Hit and Stay model, we hypothesize that EGFR binds to and
phosphorylates ATM at Y370 in response to DSBs induction. Instead of
leaving the protein complex, EGFR keeps binding with the protein complex
and further phosphorylates other DDR proteins located at DSBs. Indeed, we
showed that EGFR not only associates with ATM but also MRN (Mre11Rad50-NBS1) complex in the nucleus after IR treatment (Figure 8D). MRN
complex serves as a critical component in DDR by accumulating at DSBs in
a very short time after DSBs formation, tethering broken DNA ends, and
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recruiting more DDR proteins like ATM or γ-H2AX to DSBs for subsequently
signal transduction (Bensimon et al., 2011; Williams et al., 2010).
To current knowledge, three tyrosine phosphorylation sites (Y16, Y197
and Y429) of NBS1 and Y1125 phosphorylation of Rad50 were identified by
mass spectrometry carried out by different groups (Chen et al., 2009; Li et al.,
2009b; Olsen et al., 2010; Phanstiel et al., 2011; Rigbolt et al., 2011).
However, tyrosine kinases responsible for those phosphorylation events or
subsequent detailed functions in DDR are not clear. It requires further
experiments to elucidate whether EGFR phosphorylates those DDR proteins
and contributes their functions in DDR.

14.2 ATM conformational changes in response to DSBs formation.
ATM is known to be activated by inductions of DSBs formation,
dissociated

from

inactive

homodimer

to

active

monomer

and

autophosphorylated at S367, S1893, and S1981 (Bakkenist and Kastan,
2003; Bensimon et al., 2011; Kozlov et al., 2011). However, how dimeric and
inactive ATM dissociating as monomeric ATM with activity in response to
chromosome structural changes remains unclear. In current report, we
demonstrated that phosphorylation defective mutant ATM, Y370F, fails to
associate with EGFR (Figure 11A) and impairs ATM and downstream CHK2
IRIF (Figures 12A and 12C), implying EGFR-mediating ATM Y370
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phosphorylation may participate into activation and dissociation of dimeric
ATM.
To investigate whether ATM Y370 phosphorylation is required for
dimeric ATM dissociation, we can purify recombinant Flag-tagged ATM WT
and HA-tagged ATM Y370F proteins from 293T transfectants cells (Lee and
Paull, 2004). After sequential purification, we can analyze those ATM protein
compositions by using native gel electrophoresis followed by western blotting.
Besides, those purified ATM proteins can be used in in vitro binding assay
with MRN protein complex and the results may bring us hints regarding the
connections in those DDR proteins.

14.3 Combination therapy of targeting nuclear EGFR and radiation
Nuclear EGFR had been linked to tumor progression, poor prognosis,
radiotherapy resistance in types of cancer (Brand et al., 2013; Wang et al.,
2010). Previous reports indicated that PKCε-mediated EGFR Y654
phosphorylation,

Src

family

kinase

(SFK)-mediated

EGFR

Y1101

phosphorylation and AKT-mediated EGFR S229 phosphorylation all
contribute to EGFR nuclear translocation in human NSCLC and breast
cancer (Huang et al., 2011; Iida et al., 2013; Li et al., 2009a). Our findings
indicate nuclear EGFR-mediated ATM Y370 phosphorylation is essential for
radiotherapy resistance (Figures 13A and 13C). Therefore, we hypothesize
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impeding EGFR nuclear translocation by using inhibitors targeting PKCε,
SFK and AKT may sensitize cancer cell to radiation treatment.
To this end, we can first test whether PKCε inhibitors Enzastaurin,
Midostaurin, SFK inhibitor Dasatinib and AKT inhibitor MK2206 block
radiation-induced

EGFR

nuclear

translocation

and

ATM

Y370

phosphorylation. Next, we can further investigate whether combination of
those inhibitors with radiation enhance cancer cell radiotherapy sensitivity in
vivo and in vitro. Collectively, blockade of EGFR nuclear translocation
combines with radiation may benefit radiotherapy or chemotherapy resistant
cancer patients and improve their survival rate in the future.
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